Stereotaxis ( (STXS) ) has released its Q2 earnings. Here is a breakdown of the information Stereotaxis presented to its investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Stereotaxis, a leader in surgical robotics for minimally invasive endovascular interventions, is renowned for its innovative solutions that enhance precision and safety in operating rooms worldwide. In its latest earnings report for the second quarter of 2025, Stereotaxis announced a significant 95% increase in revenue compared to the same period last year, reaching $8.8 million. This growth is attributed to the successful commercial adoption of its new innovations, including the recently FDA-cleared MAGiC Sweep catheter, marking a pivotal achievement for the company.
The company’s financial performance highlights include a substantial increase in system revenue, which rose to $3.0 million from $0.2 million in the previous year, and recurring revenue growth of 35%, driven by the launch of the MAGiC catheter. Despite a net loss of $3.8 million, this represents an improvement from the $5.8 million loss in the prior year. Stereotaxis also reported a strengthened balance sheet following a $12.5 million equity financing, enhancing its capacity to pursue its innovation strategy.
Stereotaxis’ gross margin stood at 52%, with recurring revenue gross margin at 68%, reflecting the impact of its strategic initiatives. The company also managed to reduce its adjusted operating expenses to $6.0 million from $6.8 million in the previous year, aided by a $0.5 million Employee Retention Tax Credit. The company’s cash position was bolstered to $18.8 million following recent financing activities, positioning it well for future growth.
Looking ahead, Stereotaxis remains optimistic about achieving double-digit revenue growth for the full year 2025, with expectations of continued system revenue and scaling recurring revenue. The company anticipates further regulatory milestones and commercial launches, which are expected to drive substantial growth into 2026, reinforcing its status as a high-growth entity in the robotic surgery market.